Abstracts tagged "rheumatoid arthritis"

Abstract Number: LB23 • ACR Convergence 2025
A Phase 1 Study of Autologous CAR-Treg Cells in Refractory Rheumatoid Arthritis: Interim Report of Safety and Efficacy
Minna Kohler¹, Sally Arai², Fawad Aslam³, Gregory Challener⁴, Matthew Frigault⁴, Melissa Griffith⁵, Tamiko Katsumoto⁶, Elena Massarotti⁷, Larry Moreland⁸, Allison Rosenthal⁹, Jeffrey Sparks⁷, Janeth Yinh⁴, Sarah Baxter¹⁰, Ari Bitton¹¹, Jason Dubovsky¹², Victor Yuan¹³, Mindy Jensen¹⁴, Andrew Clauw¹⁵, Gabrielle Furman⁴, Rita Gyurko⁷, Megan Hall⁹, Anna McIntyre⁴, Jennifer Seifert¹⁶, Emma Stainton², Michelle Blake¹⁰, Sabrina Fox-Bosetti¹³, Herve Lebrec¹³, Amanda Pace¹⁰, Yuanyuan Xiao¹⁷, Mei-Lun Wang¹⁸, Joe Arron¹³ and Jeffrey Bluestone¹⁹, ¹Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, ²Stanford, Palo Alto, California, ³Mayo Clinic, Arizona, Scottsdale, Arizona, ⁴Massachusetts General Hospital, Boston, Massachusetts, ⁵University of Colorado Anschutz Medical Campus, Aurora, Colorado, ⁶Stanford University, Millbrae, California, ⁷Brigham and Women's Hospital, Boston, Massachusetts, ⁸University of Colorado, Denver, Colorado, ⁹Mayo Clinic, Phoenix, Arizona, ¹⁰Sonoma Biotherapeutics, Seattle, Washington, ¹¹Sonoma Biotherapeutics, San Diego, California, ¹²Sonoma Biotherapeutics, Thousand Oaks, California, ¹³Sonoma Biotherapeutics, South San Francisco, California, ¹⁴Sonoma Bio, Seattle, Washington, ¹⁵University of Colorado, Aurora, Colorado, ¹⁶University of Colorado and Oklahoma Medical Research Foundation, Aurora, Colorado, ¹⁷Sonoma Biotherapeutics, Los Altos, California, ¹⁸Sonoma Biotherapeutics, San Francisco, California, ¹⁹Sonoma Biotherapeutics Inc, South San Francisco, California
Background/Purpose: Regulatory T cells (Tregs) modulate inflammation, maintain self-tolerance, promote tissue repair, and hold promise as a versatile therapeutic. Autologous polyclonal Tregs have a favorable…
Abstract Number: LB05 • ACR Convergence 2025
ER Stress-Induced ATP2A3 Drives Rheumatoid Arthritis via Activation of STING Signaling
yujie cai, Nanfang hospital, Guangzhou, China (People's Republic)
Background/Purpose: Rheumatoid arthritis (RA) is an autoimmune disease characterized by persistent synovial inflammation and joint bone destruction. Endoplasmic reticulum (ER) stress plays an important role…
Abstract Number: LB15 • ACR Convergence 2025
Dietary Fiber Supplementation Enhances Methotrexate Response and Restores Th17/Treg Balance in Rheumatoid Arthritis: Results from the Superfibre Randomized Trial
Claire Immediato Daien¹, Jean-Pierre Hellier², Zübeyir Salis³, Gaël Mouterde⁴, Jacques Morel⁵, Laurence Macia⁶ and Rachel audo⁴, ¹CHU and Univesrity of Montpellier, Montpellier, France, ²CHU Montpellier, Arles, France, ³University of Montpellier, Montpellier, France, ⁴CHU Montpellier, Montpellier, France, ⁵CHU and University of Montpellier, Montpellier, France, ⁶Sydney University, Brisbane, Australia
Background/Purpose: Gut dysbiosis and Th17/Treg imbalance contribute to rheumatoid arthritis (RA). Additionally, methotrexate (MTX) efficacy depends on gut microbiota composition, especially on the presence of B.…
Abstract Number: LB19 • ACR Convergence 2025
Rosnilimab, a Selective and Potent Depleter of Pathogenic T Cells, Demonstrates Efficacy, Safety, and Translational Proof of Mechanism in a Rheumatoid Arthritis Phase 2B Trial
Jonathan Graf¹, Amy Archer², Sergiy Kovalenko³, Katarzyna Kolossa⁴, John Serpa⁵, Tamta Kobakhidze⁶, Daniela Cepoi⁷, Andrea Everding⁸, Costantino Pitzalis⁹, Catherine Aversa², Martin Dahl², May Hafez², Paul Lizzul², Priya Raina², Bruce Randazzo², Yangsu Ren², Khalil Saikali², Cailin Sibley¹⁰, Gerd Burmester¹¹, Jacques-eric GOTTENBERG¹², Iain McInnes¹³, Eduardo Mysler¹⁴, Lee Simon¹⁵, Josef Smolen¹⁶, Jeffrey Sparks¹⁷, Ronald van Vollenhoven¹⁸, Michael Weinblatt¹⁹ and Paul Emery²⁰, ¹UCSF, San Francisco, California, ²AnaptysBio Inc, San Diego, California, ³Arensia Exploratory Medicine, Kyiv, Ukraine, ⁴MICS Centrum Medyczne, Bydgoszcz, Poland, ⁵Allied Biomedical Research Institute, Miami, Florida, ⁶Research Institute of Clinical Medicine Todua Clinic, Tbilisa, Georgia, ⁷Nicolae Testemitanu State University of Medicine & Pharmacy, Chisinau, Moldova, ⁸MVZ Rheumatologie & Autoimmunmedzin Hamburg GmbH, Hamburg, Germany, ⁹QMUL, Bromley Kent, United Kingdom, ¹⁰AnaptysBio Inc, San Diego, ¹¹Charité - Universitétsmedizin Berlin, Berlin, Germany, ¹²Hautepierre Hospital, STRASBOURG, France, ¹³University of Glasgow, Glasgow, United Kingdom, ¹⁴OMI, Buenos Aires, Argentina, ¹⁵SDG LLC, West Newton, Massachusetts, ¹⁶Medical University of Vienna, Vienna, Austria, ¹⁷Brigham and Women's Hospital, Boston, Massachusetts, ¹⁸Amsterdam UMC, Amsterdam, Netherlands, ¹⁹Brigham and Women's Hospital/ Harvard Medical School, Waban, Massachusetts, ²⁰University of Leeds, Leeds, United Kingdom
Background/Purpose: Over 50% of RA patients require multiple b/tsDMARD classes due to inadequate or lost response. Rosnilimab, an investigational monoclonal antibody that selectively targets and…
Abstract Number: 0491 • ACR Convergence 2025
Association of Short Chain Fatty Acids and Diet with Disease Activity and Methotrexate Response in New Onset Rheumatoid Arthritis: A Proof of Principle Study
Kaci French¹, Luz Alvarado², Rebecca Haberman³ and Rebecca Blank³, ¹NYU Langone, New York, NY, ²NYU Langone, New York, ³NYU Langone Health, New York, NY
Background/Purpose: Diet, the gut microbiome, and gut microbial metabolites have been implicated in rheumatoid arthritis (RA) development and modulation. Seafood based-omega-3 fatty acids modulate inflammatory…
Abstract Number: 0475 • ACR Convergence 2025
Drug Discontinuation in Inflammatory Arthritis Following Mandatory Non-Medical Switching from Originator to Biosimilar in Quebec, Canada
Cristiano Moura¹, Luck Lukusa², Denis Choquette³, Gilles Boire⁴, Nathalie Carrier⁵, Autumn Neville² and Sasha Bernatsky⁶, ¹Research Institute of the McGill University Health Center, Montréal, Canada, ²Research Institute of the McGill University Health Centre, Montreal, Canada, ³Institut de Rhumatologie de Montréal, Saint-Donat-de-Montcalm, Canada, ⁴Retired, Sherbrooke, QC, Canada, ⁵Centre integré universitaire de santé et de services sociaux de l’Estrie – Centre hospitalier universitaire de Sherbrooke (CIUSSS de l’Estrie-CHUS), Sherbrooke, Canada, ⁶Research Institute of the McGill University Health Centre, Montreal, QC, Canada
Background/Purpose: In April 2022, the Canadian province of Quebec introduced a mandatory non-medical switch to biosimilars for persons on bio-originators to manage healthcare costs. Our…
Abstract Number: 0459 • ACR Convergence 2025
Risk Factors for Acute Exacerbation in Patients with Rheumatoid Arthritis-associated Interstitial Lung Disease
Rinko Katsuda¹, Akiko Kitagawa¹, Masayuki Azukizawa², Musuzu Fujimori¹ and Tetsuji Kawamura³, ¹Department of Rheumatology, NHO Himeji Medical Center, Japan, Himeji, Japan, ²Department of Orthopaedic Surgery, NHO Himeji Medical Center, Japan, Himeji, Japan, ³Department of Respiratory Medicine, NHO Himeji Medical Center, Japan, Himeji, Japan
Background/Purpose: Rheumatoid arthritis-associated interstitial lung disease (RA-ILD) is a common and serious extra-articular manifestation of RA, contributing to ~10% of RA-related mortality. Acute exacerbation (AE)…
Abstract Number: 0442 • ACR Convergence 2025
Beyond the Joints: The Impact of Non-Articular Pain on Patient-Reported Function in a Longitudinal Real-World Early RA Cohort
Charis Meng¹, Marie-France Valois², Caci Julia³, Yvonne Lee⁴, Bindee Kuriya⁵, Gilles Boire⁶, Hugues Allard-Chamard⁷, Carol Hitchon⁸, Louis Bessette⁹, Glen Hazlewood¹⁰, Carter Thorne¹¹, Susan J. Bartlett¹², Janet Pope¹³ and Vivian Bykerk¹, ¹Hospital for Special Surgery, New York, NY, ²McGill University, Pointe-Claire, QC, Canada, ³Hospital for Special Surgery, New York, ⁴Northwestern University, Chicago, IL, ⁵Mount Sinai Health, Toronto, Canada, ⁶Retired, Sherbrooke, QC, Canada, ⁷Université de Sherbrooke, Sherbrooke, Canada, ⁸University of Manitoba, Winnepeg, Canada, ⁹Centre de l'Ostéoporose et de Rhumatologie de Québec, Quebec, QC, Canada, ¹⁰University of Calgary, Calgary, AB, Canada, ¹¹Southlake Regional Health Centre, Newmarket, ON, Canada, ¹²McGill University, Beaconsfield, QC, Canada, ¹³University of Western Ontario, London, ON, Canada
Background/Purpose: A third of patients with early (e)RA report pain outside the joint or non-articular pain (NAP) despite RA treatment(1). NAP, both regional and widespread,…
Abstract Number: 0369 • ACR Convergence 2025
Real-World Persistence of Janus Kinase Inhibitors in Biologic-Experienced Patients with Rheumatoid Arthritis
Jeffrey Curtis¹, Emily Holladay², Nick McCormick³, Yujie Su⁴, Fenglong Xie¹ and Alexis Dineen⁵, ¹University of Alabama at Birmingham, Birmingham, AL, ²University of Alabama at Birmingham, Edmond, OK, ³Auburn University, Auburn, AL, ⁴University of Alabama at Birimingham, Birmingham, AL, ⁵Self, Portola Valley, CA
Background/Purpose: Over the last decade, Janus kinase inhibitors (JAKs) for RA have been increasingly used as a treatment option for patients who do not respond…
Abstract Number: 0197 • ACR Convergence 2025
Rheumatoid arthritis (RA) patients who screen positive for anxiety, depression, and/or fibromyalgia are more likely to report problems with sleeping, memory, and/or social activities than to have an abnormal rheumatoid factor or ACPA
Theodore Pincus¹, Juan Schmukler¹ and Tengfei Li², ¹Rush University Medical Center, Chicago, IL, ²Rush, chicago, IL
Background/Purpose: A symptom checklist and screening indices for anxiety (ANX), depression (DEP), and/or fibromyalgia (FM) on patient questionnaires such as a multidimensional health assessment questionnaire…
Abstract Number: 0097 • ACR Convergence 2025
Aberrant histone marks increase the inflammatory phenotype of rheumatoid arthritis fibroblast-like synoviocytes (RA FLS) by suppressing NUB1 induction
Yosuke Ono¹, Camilla R.L. Machado², Eunice Choi¹, Wei Wang¹, David Boyle¹ and Gary Firestein², ¹University of California, San Diego, San Diego, ²University of California, San Diego, San Diego, CA
Background/Purpose: Fibroblast-like synoviocytes (FLS) play a central role in cartilage destruction and cytokine production in rheumatoid arthritis (RA). Neddylation, a post-translational modification involving NEDD8 conjugation,…
Abstract Number: 0077 • ACR Convergence 2025
Transformer-based multi-omics study identifies important role of glycine, serine and threonine metabolism pathway in rheumatoid arthritis complicated by anemia
Fanxin zeng¹, Jianxin Huang², Yuanli Wei³, Dongmei Wang³, Jianghua Chen⁴, Congcong Jian¹, Xiaoting Zhu⁵, Shilin Li⁵, Jie Zhang⁵, Tingting Wang³, Caizhen Liu⁶, Lingli Wei³, Jing Gao³, Jing Zhu⁷, Qinghua Zou⁸ and Jianhong Wu³, ¹Departmant of Clinical Research Center, Sichuan Clinical Research Center for Medical Imaging, Dazhou Central Hospital; Medical School, Sichuan University of Arts and Sciences; School of Basic Medical Science, Chengdu University of Traditional Chinese Medicine, Dazhou, China (People's Republic), ²Institute of Basic Medicine and Forensic Medicine, North Sichuan Medical College, Nanchong, China (People's Republic), ³Department of Rheumatology and Immunology, Dazhou Central Hospital, Dazhou, China (People's Republic), ⁴Dazhou Vocational College of Chinese Medicine, Dazhou, China (People's Republic), ⁵Departmant of Clinical Research Center, Sichuan Clinical Research Center for Medical Imaging, Dazhou Central Hospital, Dazhou, China (People's Republic), ⁶Department of Rheumatology and Immunology, Dazhou Central Hospital, Dazhou, ⁷Department of Rheumatology and Immunology, Sichuan Provincial People's Hospital, Chengdu, China (People's Republic), ⁸Department of Rheumatology and Immunology, First Affiliated Hospital of Army Medical University, Chongqing, China (People's Republic)
Background/Purpose: Anemia is a prevalent hematologic complication of rheumatoid arthritis (RA) that exacerbates the disease process and severely impacts clinical performance and treatment strategies. We…
Abstract Number: 0057 • ACR Convergence 2025
TNF Inhibition with Small-molecule Agents Results in Amelioration of Inflammation Similar to that of Anti-TNF Biologics While Preserving TNFR2 Signaling and Maintaining a Suppressive Regulatory T cell Phenotype
Rajesh Singh¹, Bindi Patel², Rameshwari Rayaji², Archana Sidalaghatta Nagaraja², Saranya Chandrasekar², Yihong Guan², Ritu Kushwaha², Yue Tong Lee², Cesar Meleza², Matthew Epplin², Brandon Rosen², Manmohan R Leleti², Matthew J Walters² and Daniel DiRenzo², ¹Arcus Biosciences, inc., Santa Clara, CA, ²Arcus Biosciences, inc., Hayward, CA
Background/Purpose: Anti-TNF biologics are effective in the treatment of inflammatory diseases such as rheumatoid arthritis and psoriasis. However, they can lead to de novo inflammation…
Abstract Number: 2683 • ACR Convergence 2025
Association of Genetic Risk for Pain Intensity with Longitudinal Disease Activity in Rheumatoid Arthritis
Stevie Barry¹, Katie McMenamin², Austin Wheeler³, Bryant England³, Grant Cannon⁴, Brian Sauer⁵, Gary Kunkel⁶, Katherine Wysham⁷, Beth Wallace⁸, Andreas Reimold⁹, Gail Kerr¹⁰, Isaac Smith¹¹, John Richards¹², Iris Lee¹³, Rui Xiao¹, Sylvanus Toikumo¹⁴, Henry Kranzler¹⁴, Rachel Kember¹⁴, Scott Damrauer¹⁴, Michael Levin¹⁴, Michael George¹, Ted Mikuls³, Joshua Baker¹ and Thomas Riley¹, ¹University of Pennsylvania, Philadelphia, PA, ²Boston Medical Center, Boston, MA, ³University of Nebraska Medical Center, Omaha, NE, ⁴University of Utah and Salt Lake City VA, Salt Lake City, UT, ⁵Salt Lake City VA/University of Utah, Salt Lake City, UT, ⁶University of Utah and George E Wahlen VAMC, Salt Lake City, UT, ⁷VA PUGET SOUND/UNIVERSITY OF WASHINGTON, Seattle, WA, ⁸Michigan Medicine, VA Ann Arbor Healthcare System, Ann Arbor, MI, ⁹Dallas VA Medical Center, Dallas, TX, ¹⁰Washington DC VAMC/Georgetown and Howard Universities, Washington, DC, ¹¹Duke University Hospital, Durham, NC, ¹²Veterans Affairs Pittsburgh Healthcare System, Pittsburgh, PA, ¹³Washington University in St Louis, Saint Louis, MO, ¹⁴University of Pennsylvania / Corporal Michael J. Crescenz VAMC, Philadelphia, PA
Background/Purpose: Guidelines recommend the use of composite scores to evaluate disease activity in RA and inform a treat-to-target approach. It is recognised that patient-reported components…
Abstract Number: 2614 • ACR Convergence 2025
Impact of Vagus Nerve-Mediated Neuroimmune Modulation on structural joint damage using Gd-MRI RAMRIS imaging in Biologic-Experienced Patients with Rheumatoid Arthritis
Charles Peterfy, MD, PhD¹, John Tesser², Yaakov Levine³, Melissa Evangelista⁴, Vibeke Strand⁵, Michael Weinblatt⁶ and David Chernoff⁷, ¹Spire Sciences, Inc., Boca Raton, FL, ²Arizona Arthritis & Rheumatology Associates, Phoenix, AZ, ³SetPoint Medical, Valencia, CA, ⁴SetPoint Medical Corporation, Valencia, CA, ⁵Stanford University School of Medicine, Palo Alto CA, Portola Valley, CA, ⁶Brigham and Women's Hospital/ Harvard Medical School, Waban, MA, ⁷SetPoint Medical, Sausalito, CA
Background/Purpose: Previously reported results from RESET-RA (ClinicalTrials.gov, NCT04539964) showed neuroimmune modulation via electrical stimulation of the left vagus nerve using an implantable device to treat…

1
2
3
…
219
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].